Healthcare / BiotechnologyNasdaqCM
$0.29
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-10.3M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
2/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$3M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-209.4%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-11.1M · FCF $-10.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | $119371.00 | $839359.00 | $948911.00 | $824268.00 | $2.4M | $4.6M | $5.2M | $5.4M | $10.4M | $8.8M | $7.0M | $3.2M | $3.1M | $7.7M | $1.9M |
| Net Income | $-11.1M | $-11.1M | $-8.3M | $-6.1M | $-13.8M | $-12.6M | $-17.7M | $-9.4M | $-8.9M | $-7.1M | $-3.2M | $-7.8M | $-6.7M | $-10.1M | $-4.2M | $-2.4M | $-7.4M |
| EBITDA | — | — | — | — | — | $-13.1M | $-18.5M | $-10.5M | $-9.0M | $-7.5M | $-5.6M | $-6.9M | $-10.5M | $-6.9M | $-4.5M | $-2.7M | $-7.7M |
| EPS | -2.14 | -2.14 | -4.98 | -12.66 | -4.81 | -4.69 | -0.64 | — | — | -1.16 | -1.34 | -3.00 | -0.43 | -0.65 | — | — | — |
| Gross Margin | — | — | — | 11.6% | 42.0% | 11.6% | 22.8% | 22.9% | 12.3% | 20.7% | 19.3% | 21.5% | 24.6% | 21.1% | 17.5% | 72.5% | 15.9% |
| Operating Margin | — | — | -7907.7% | -917.1% | -1500.6% | -1589.2% | -787.7% | -227.7% | -172.8% | -139.8% | -54.6% | -81.1% | -152.8% | -222.0% | -149.2% | -38.6% | -404.5% |
| Net Margin | — | — | -6925.1% | -731.6% | -1454.1% | -1522.7% | -749.7% | -202.1% | -169.8% | -131.6% | -31.1% | -89.3% | -95.2% | -312.0% | -132.4% | -31.0% | -379.3% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | — | — | 0.00 | 0.40 | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-10.3M | $-10.3M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Returns | |||||||||||||||||
| ROE | -209.4% | -209.4% | -200.7% | -243.4% | 558.5% | -117.1% | -472.7% | -642.1% | -141.7% | -113.1% | -43.9% | 42772.6% | 4358.3% | 568.4% | -117.2% | -35.0% | -100.4% |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | -85.8% | -11.5% | 15.1% | -65.1% | -49.0% | -11.7% | -3.5% | -48.0% | 19.2% | 24.5% | 118.4% | 2.5% | -59.0% | 293.4% | — |
| EPS Growth | 57.0% | 57.0% | 60.7% | -163.2% | -2.6% | -632.8% | — | — | — | 13.4% | 55.3% | -597.7% | 33.8% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.